Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    spi-zev-11-301
Show Display Options
Rank Status Study
1 Terminated Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy
Conditions: Diffuse Large B-cell Lymphoma;   Follicle Center Lymphoma
Intervention: Drug: Zevalin (ibritumomab tiuxetan)

Indicates status has not been verified in more than two years